Viridian Therapeutics' (VRDN) Buy Rating Reiterated at HC Wainwright

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $34.00 price objective on the stock. HC Wainwright's target price suggests a potential upside of 147.09% from the company's current price.

Separately, Needham & Company LLC reissued a "buy" rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Viridian Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $35.70.

Viridian Therapeutics Stock Up 4.8 %

Shares of NASDAQ VRDN opened at $13.76 on Wednesday. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -3.19 and a beta of 0.81. Viridian Therapeutics has a 52 week low of $9.90 and a 52 week high of $27.20. The firm has a 50-day moving average price of $14.40 and a 200 day moving average price of $18.44.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.24. The business had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Equities research analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current fiscal year.

Institutional Investors Weigh In On Viridian Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VRDN. SG Americas Securities LLC grew its position in shares of Viridian Therapeutics by 2.9% during the 1st quarter. SG Americas Securities LLC now owns 31,972 shares of the company's stock worth $431,000 after buying an additional 887 shares during the period. Voya Investment Management LLC grew its stake in Viridian Therapeutics by 5.1% in the fourth quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock valued at $410,000 after acquiring an additional 1,038 shares during the period. Tudor Investment Corp ET AL raised its holdings in Viridian Therapeutics by 3.0% during the 4th quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after buying an additional 1,106 shares during the period. R Squared Ltd bought a new stake in Viridian Therapeutics in the 4th quarter valued at $26,000. Finally, Summit Investment Advisors Inc. grew its holdings in shares of Viridian Therapeutics by 24.7% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock worth $147,000 after buying an additional 1,516 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.